Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest HCV Stories

2013-11-21 08:28:22

Surveyed Physicians Expect Nearly 20 Percent of Their Actively Treated HCV Patients to Be On a Newly Approved Regimen, According to a New Report from BioTrends Research Group EXTON, Pa., Nov. 21, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, following the launches of Gilead's sofosbuvir and Janssen/Medivir's simeprevir in the United States, currently marketed triple (Vertex's...

2013-11-18 08:28:30

- Confirms results of phase II studies, with consistent virologic response and tolerability profile NORTH CHICAGO, Ill., Nov. 18, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) released the first phase III results for the investigational three direct-acting-antiviral (3D) regimen plus ribavirin in patients chronically infected with genotype 1 (GT1) hepatitis C virus (HCV). In the 631-patient SAPPHIRE-I study, patients new to therapy receiving 12 weeks of AbbVie's 3D regimen achieved...

2013-11-11 13:14:01

More damage seen when FOXO3 suppressed, according to report in The American Journal of Pathology New data suggest that the transcription factor FOXO3 may protect against alcohol-induced liver injury. Researchers determined that alcohol given to mice deficient in FOXO3 caused severe liver injury resembling human alcoholic hepatitis. Further they found that although hepatitis C virus (HCV) and alcohol independently activated FOXO3, in combination they suppressed FOXO3, reduced expression of...

2013-11-05 23:02:30

Leading experts convene and issue a Consensus Panel paper on Hepatitis C; which provides an undeniably clear roadmap for addressing this health disparity. The National Medical Association raises the alarm for African Americans and calls for an aggressive approach. Silver Spring, MD (PRWEB) November 05, 2013 The National Medical Association (NMA) today released the much anticipated Consensus Panel Paper entitled: Hepatitis C: A Crisis in the African American Community. The NMA is the...

2013-11-04 08:27:35

Presented: November 5, 2013 at the Walter E. Washington Convention Center, Washington, DC WASHINGTON, Nov. 4, 2013 /PRNewswire/ -- For the first time, researchers have been able to prevent the recurrence of hepatitis C virus (HCV) infection in a large proportion of patients (64 percent, n=25/39) who undergo liver transplantation for cirrhosis complicated by hepatocellular carcinoma (HCC). This success was achieved with an interferon-free treatment regimen containing the oral...

2013-11-04 08:26:24

- Late-Breaking Poster to be Presented at AASLD - LA JOLLA, Calif., Nov. 4, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that data demonstrating the positive preclinical profile of RG-101 will be presented in a late-breaking poster session at the 64th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) being...

2013-11-02 08:21:43

Presented: November 3, 2013; Walter E. Washington Convention Center, Washington, DC WASHINGTON, Nov. 2, 2013 /PRNewswire/ -- In 2012, the Centers for Disease Control and Prevention (CDC) recommended a one-time screening for all Americans born between 1945 and 1965. It is estimated that 1 in 30 baby boomers has been infected with hepatitis C virus (HCV) and most don't know it. HCV is a serious liver disease including liver cancer, which is the fastest-rising cause of cancer-related...

2013-11-02 08:21:34

Multiple studies presented at The Liver MeetingĀ® investigating faldaprevir include difficult-to-cure patient populations, such as those with HIV/HCV coinfection and advanced liver disease RIDGEFIELD, Conn., Nov. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced new data from its Phase 3 clinical trial program, STARTVerso(TM), which evaluates the investigational protease inhibitor, faldaprevir, in combination with pegylated interferon and ribavirin...

2013-11-02 08:21:30

Clinical trial studies an all-oral, 12-week regimen containing the investigational compounds faldaprevir, deleobuvir, and Presidio Pharmaceuticals' PPI-668 with and without ribavirin in 36 difficult-to-treat genotype-1a HCV patients RIDGEFIELD, Conn., Nov. 2, 2013 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim data from its Phase 2a hepatitis C (HCV) clinical collaboration (NCT01859962) with Presidio Pharmaceuticals, Inc. that showed all patients (13/13)...

2013-11-02 08:21:21

Sustained virologic response at post-treatment follow-up week 12 (SVR 12) seen in 100 per cent of patients to date in two of the three combination arms studied MONTREAL, Nov. 2, 2013 /CNW/ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced interim results from an ongoing Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease...


Latest HCV Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »